FTC Probes King Pharmaceuticals In Antitrust Inquiry

Law360, New York (May 10, 2006, 12:00 AM EDT) -- As part of its investigation into the potential anti-competitive effects of authorized generics of brand-name drugs, the Federal Trade Commission has requested information from King Pharmaceuticals Inc. related to a patent infringement suit against a generic drug maker over the hypertension drug Altace.

The pharmaceutical company said it was cooperating in the matter with the FTC, according to a filing Wednesday with the U.S. Securities and Exchange Commission.

Beginning in March, the FTC launched an investigation to determine whether the practice of authorized generics violates antitrust...
To view the full article, register now.